Centaurus Financial’s Acadia Pharmaceuticals ACAD Stock Holding History

Centaurus Financial’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-11,050	Closed	-$169K	–	543
2018 Q2	$169K	Buy	+11,050	New	+$197K	0.02%	553

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Centaurus Financial's ACAD Position: Q3 2018 in Review

Centaurus Financial sold out of Acadia Pharmaceuticals (ACAD) in Q3 2018, closing a stake of 11,050 shares — an estimated $169K sold.

Centaurus Financial first reported a position in ACAD in Q2 2018 and held it in 1 quarter. The position peaked at $169K in Q2 2018. 184 funds tracked by Wall St. Rank hold ACAD as of Q3 2018.

Centaurus Financial reported no remaining Acadia Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Centaurus Financial sold 11,050 Acadia Pharmaceuticals shares in Q3 2018, an estimated $169K.
Centaurus Financial first reported a position in Acadia Pharmaceuticals in Q2 2018 and held it in 1 quarter.
Centaurus Financial's Acadia Pharmaceuticals position peaked at $169K in Q2 2018.
184 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.